Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

Phase 2

Ziopharm